BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 11095350)

  • 1. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of colorectal cancer.
    Winawer SJ
    Surg Oncol Clin N Am; 2005 Oct; 14(4):699-722. PubMed ID: 16226687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of immunological fecal occult blood testing for colorectal cancer screening.
    Nakama H; Kamijo N
    Prev Med; 1994 May; 23(3):309-13. PubMed ID: 8078851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for colorectal cancer.
    Hakama M; Hoff G; Kronborg O; Påhlman L
    Acta Oncol; 2005; 44(5):425-39. PubMed ID: 16118076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering.
    Thompson NJ; Boyko EJ; Dominitz JA; Belcher DW; Chesebro BB; Stephens LM; Chapko MK
    Prev Med; 2000 Mar; 30(3):244-51. PubMed ID: 10684748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
    Yamamoto M; Nakama H
    Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
    Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
    Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of colorectal cancer screening with fecal occult blood detection.
    Tárraga López PJ; Marín Nieto E; Celada Rodríguez A; García Molinero MJ; García Olmo D; Solera Albero J
    Rev Esp Enferm Dig; 2000 May; 92(5):334-48. PubMed ID: 10927933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.